APA (7th ed.) Citation

DH, K., S, K., S, C., RS, Ö., J, H., DY, S., . . . JM, B. (2025). Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea. Therapeutic advances in hematology, 16, 20406207251406461. https://doi.org/10.1177/20406207251406461

Chicago Style (17th ed.) Citation

DH, Kim, Kwon S, Cha S, Öz RS, Hong J, Shin DY, Koh Y, Yoon SS, and Byun JM. "Real-world Experience with Tisagenlecleucel for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma in Korea." Therapeutic Advances in Hematology 16 (2025): 20406207251406461. https://doi.org/10.1177/20406207251406461.

MLA (9th ed.) Citation

DH, Kim, et al. "Real-world Experience with Tisagenlecleucel for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma in Korea." Therapeutic Advances in Hematology, vol. 16, 2025, p. 20406207251406461, https://doi.org/10.1177/20406207251406461.